Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:RCKT NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$9.75+4.8%$7.70$5.90▼$29.61$715.85M2.392.14 million shs1.91 million shsRCKTRocket Pharmaceuticals$3.39+8.0%$3.20$2.19▼$18.89$365.78M0.63.52 million shs5.34 million shsXNCRXencor$12.40+3.1%$8.92$6.92▼$27.24$884.37M0.96813,930 shs960,600 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-3.33%+9.15%+18.77%+13.00%-63.23%RCKTRocket Pharmaceuticals-1.26%-3.68%-4.27%-1.88%-81.28%XNCRXencor+2.04%+2.56%+40.70%+28.94%-38.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$9.75+4.8%$7.70$5.90▼$29.61$715.85M2.392.14 million shs1.91 million shsRCKTRocket Pharmaceuticals$3.39+8.0%$3.20$2.19▼$18.89$365.78M0.63.52 million shs5.34 million shsXNCRXencor$12.40+3.1%$8.92$6.92▼$27.24$884.37M0.96813,930 shs960,600 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-3.33%+9.15%+18.77%+13.00%-63.23%RCKTRocket Pharmaceuticals-1.26%-3.68%-4.27%-1.88%-81.28%XNCRXencor+2.04%+2.56%+40.70%+28.94%-38.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.48Hold$16.2967.07% UpsideRCKTRocket Pharmaceuticals 2.33Hold$16.67391.64% UpsideXNCRXencor 2.55Moderate Buy$24.2295.34% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, RCKT, and XNCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RCKTRocket PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025ARVNArvinasPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$16.0010/6/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.0010/3/2025RCKTRocket PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$9.00 ➝ $7.009/27/2025ARVNArvinasWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RCKTRocket PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/24/2025ARVNArvinasBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$10.009/18/2025ARVNArvinasWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $9.009/18/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $10.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.72N/AN/A$8.17 per share1.19RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/AXNCRXencor$110.49M8.00N/AN/A$9.63 per share1.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest ARVN, RCKT, and XNCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025XNCRXencor-$0.72N/AN/AN/A$29.73 millionN/A10/29/2025Q3 2025ARVNArvinas-$0.74N/AN/AN/A$29.36 millionN/A8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.645.64RCKTRocket Pharmaceuticals0.056.396.39XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%RCKTRocket Pharmaceuticals98.39%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas4.73%RCKTRocket Pharmaceuticals24.76%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42073.42 million69.95 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableXNCRXencor28071.32 million67.59 millionOptionableARVN, RCKT, and XNCR HeadlinesRecent News About These CompaniesCantor Fitzgerald Reaffirms Overweight Rating for Xencor (NASDAQ:XNCR)October 8 at 2:51 AM | americanbankingnews.comCantor Fitzgerald Forecasts Xencor FY2025 EarningsOctober 7 at 8:10 AM | marketbeat.comXencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor FitzgeraldOctober 6 at 9:45 AM | marketbeat.comXencor (NASDAQ:XNCR) Trading 6.2% Higher - Should You Buy?September 26, 2025 | marketbeat.comXencor: Bispecific Antibody Program Takes Shape With Q4 Data ReleaseSeptember 19, 2025 | seekingalpha.comXencor (XNCR) Receives a Sell from Roth MKMSeptember 19, 2025 | theglobeandmail.comXencor (NASDAQ:XNCR) Upgraded to "Strong Sell" at BarclaysSeptember 19, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading Up 5.4% - Time to Buy?September 18, 2025 | marketbeat.comStrength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?September 18, 2025 | zacks.comXencor (NASDAQ:XNCR) Given "Underweight" Rating at BarclaysSeptember 18, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 17, 2025 | marketbeat.comXencor initiated with an Underweight at BarclaysSeptember 16, 2025 | msn.comXencor assumed with an Underweight at BarclaysSeptember 16, 2025 | msn.comGoldman Sachs Group Inc. Has $7.73 Million Stock Position in Xencor, Inc. $XNCRSeptember 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Buys 384,509 Shares of Xencor, Inc. $XNCRSeptember 10, 2025 | marketbeat.com155,580 Shares in Xencor, Inc. $XNCR Bought by Cubist Systematic Strategies LLCSeptember 9, 2025 | marketbeat.comTrexquant Investment LP Acquires 50,119 Shares of Xencor, Inc. $XNCRSeptember 8, 2025 | marketbeat.comRBC Cuts Xencor (XNCR) Price Target but Keeps Outperform RatingSeptember 8, 2025 | msn.comB of A Securities Downgrades Xencor (XNCR)September 4, 2025 | msn.comXencor downgraded to Neutral from Buy at BofASeptember 3, 2025 | msn.comBeyond The Numbers: 4 Analysts Discuss Xencor StockSeptember 3, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, RCKT, and XNCR Company DescriptionsArvinas NASDAQ:ARVN$9.75 +0.45 (+4.84%) Closing price 04:00 PM EasternExtended Trading$9.65 -0.10 (-0.97%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Rocket Pharmaceuticals NASDAQ:RCKT$3.39 +0.25 (+7.96%) Closing price 04:00 PM EasternExtended Trading$3.44 +0.05 (+1.47%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Xencor NASDAQ:XNCR$12.40 +0.37 (+3.08%) Closing price 04:00 PM EasternExtended Trading$12.53 +0.13 (+1.04%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Will Firefly’s $855M SciTec Acquisition Ignite a Stock Re-Rating? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
